{
    "clinical_study": {
        "@rank": "68906", 
        "arm_group": [
            {
                "arm_group_label": "Riluzole", 
                "arm_group_type": "Experimental", 
                "description": "Riluzole 50 mg orally twice per day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo orally twice per day"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled, parallel group study will evaluate the\n      safety and efficacy of riluzole in patients with PTSD. Patients will be randomized to\n      receive either riluzole 50mg twice per day or placebo orally for 8 weeks as outpatient, with\n      a 4-week open-label period."
        }, 
        "brief_title": "A Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)", 
        "condition": "PTSD", 
        "condition_browse": {
            "mesh_term": [
                "Stress Disorders, Post-Traumatic", 
                "Stress Disorders, Traumatic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PTSD participants\n\n        Inclusion Criteria:\n\n          -  Male or female subjects between the ages of 18-50 years;\n\n          -  Able to provide written informed consent;\n\n          -  Current Post Traumatic Stress Disorder;\n\n          -  Clinician Administered PTSD Scale for DSM-IV-TR (CAPS) score of 50 or higher;\n\n          -  Be able to understand and speak English;\n\n        Exclusion Criteria:\n\n          -  Breastfeeding women and pregnant women, or women of child bearing potential who are\n             not using a medically accepted means of contraception;\n\n          -  Any history indicating learning disability, mental retardation, or attention deficit\n             disorder;\n\n          -  Serious suicide or homicide risk;\n\n          -  Unstable medical illness;\n\n          -  Substance use disorders active within the last three months, bipolar disorder\n             (current or past), psychotic disorder (current or past);\n\n          -  History of a seizure disorder or clinical evidence of untreated hypothyroidism;\n\n          -  Patients requiring excluded medications\n\n          -  Psychotic features in the current episode or a history of psychotic features;\n\n          -  Patients with a history of antidepressant-induced hypomania;\n\n          -  Patients with any evidence of clinically significant liver abnormalities, or any\n             liver transaminase level > 1.5 x ULN at initial screening, or > 5 x ULN during\n             treatment;\n\n          -  Axis II personality disorders that are the primary purpose of treatment, or would\n             interfere with a patient's safety or compliance;\n\n          -  Patients currently being treated for a respiratory disorder (including asthma or\n             COPD);\n\n          -  Structured psychotherapy focused on treatment of PTSD is exclusionary unless the\n             subject has had at least 8 weeks of treatment prior to randomization;\n\n        Healthy Participants\n\n        Inclusion Criteria:\n\n          -  Male or female between the ages of 18-50 years;\n\n          -  Able to provide written informed consent;\n\n          -  Be able to understand and speak English.\n\n        Exclusion Criteria:\n\n          -  Breastfeeding women and pregnant women, or women of child bearing potential who are\n             not using a medically accepted means of contraception;\n\n          -  Any lifetime history of DSM-IV-TR mood, anxiety, psychotic or personality disorders\n             confirmed after comprehensive psychiatric evaluation;\n\n          -  Any history of serious medical or neurological illness;\n\n          -  Unstable medical illness;\n\n          -  Substance or alcohol dependence or abuse active within the last three months;\n\n          -  Any history indicating learning disability, mental retardation, or attention deficit\n             disorder;\n\n          -  History of significant head injury or other trauma resulting in a loss of\n             consciousness for 30 minutes or more;\n\n          -  History of a seizure disorder or clinical evidence of untreated hypothyroidism;\n\n          -  Subjects currently being treated for a respiratory disorder (including asthma or\n             COPD);\n\n          -  History of claustrophobia as determined by open-ended psychiatric interview;\n\n          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal\n             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening\n             questionnaire."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019940", 
            "org_study_id": "1308012549"
        }, 
        "intervention": [
            {
                "arm_group_label": "Riluzole", 
                "intervention_name": "Riluzole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Riluzole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 18, 2013", 
        "link": {
            "description": "National Center for PTSD", 
            "url": "http://www.ptsd.va.gov/"
        }, 
        "location": {
            "contact": {
                "email": "heather.douglas-palumberi@yale.edu", 
                "last_name": "Heather Douglas-Palumbri, MA", 
                "phone": "203-932-5711", 
                "phone_ext": "5314"
            }, 
            "facility": {
                "address": {
                    "city": "West Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06516"
                }, 
                "name": "Clinical Neuroscience Division, National Center for PTSD"
            }, 
            "investigator": {
                "last_name": "Chadi Abdallah, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Structural and Spectroscopy Pharmaco-Imaging Paradigm to Investigate the Effect of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)", 
        "other_outcome": {
            "measure": "Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "overall_contact": {
            "email": "heather.douglas-palumberi@yale.edu", 
            "last_name": "Heather Douglas-Palumberi, M.A.", 
            "phone": "203 932 5711", 
            "phone_ext": "5314"
        }, 
        "overall_official": {
            "affiliation": "National Center for PTSD / Yale University", 
            "last_name": "Chadi Abdallah, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Clinician Administered PTSD Scale (CAPS)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019940"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Chadi Abdallah", 
            "investigator_title": "Assistant Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Post-Traumatic Stress Disorder Checklist (PCL)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Clinical Global Impressions Scale", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Montgomery-Asberg Depression Rating Scale (MADRS)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Hamilton Anxiety Rating Scale (HAM-A)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Center for PTSD", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}